October 18, 2024 10:29 AM EDTUpdated 03:21 PM
R&D
Pharma

Pfiz­er ends tri­al of Ar­ray-ac­quired SHP2 in­hibitor af­ter sim­i­lar cuts from peers

Kyle LaHucik

Senior Reporter

Pfiz­er has end­ed its tri­al of an SHP2 in­hibitor that was be­ing de­vel­oped in can­cer, the lat­est blow to the tar­get af­ter sev­er­al oth­er drug­mak­ers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times